Ondrej Kodet
Overview
Explore the profile of Ondrej Kodet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Polgarova K, Polivka J, Kodet O, Klener P, Trneny M
Front Oncol
. 2022 Jun;
12:884091.
PMID: 35747818
Cutaneous T-cell lymphomas (CTCL) represent rare non-Hodgkin lymphomas (NHL) with an incidence less than 1 per 100,000 inhabitants. The most common type of CTCL is mycosis fungoides (MF), which represents...
2.
Spanko M, Strnadova K, Pavlicek A, Szabo P, Kodet O, Valach J, et al.
Int J Mol Sci
. 2021 Oct;
22(20).
PMID: 34681685
Interleukin-6 (IL-6) is a highly potent cytokine involved in multiple biological processes. It was previously reported to play a distinct role in inflammation, autoimmune and psychiatric disorders, ageing and various...
3.
Rekova P, Dostalova G, Kemlink D, Paulasova Schwabova J, Dubska Z, Vaneckova M, et al.
J Clin Med
. 2021 Aug;
10(16).
PMID: 34441839
Fabry disease (FD) is a rare X-linked disorder of glycosphingolipid metabolism caused by pathogenic variants within the alpha-galactosidase A (GLA) gene, often leading to neurological manifestations including stroke. Multiple screening...
4.
Kodet O, Nemejcova K, Strnadova K, Havlinova A, Dundr P, Krajsova I, et al.
Int J Mol Sci
. 2021 Jul;
22(13).
PMID: 34281259
Therapy targeting immune checkpoints represents an integral part of the treatment for patients suffering from advanced melanoma. However, the mechanisms of resistance are responsible for a lower therapeutic outcome than...
5.
Stolarova L, Jelinkova S, Storchova R, Machackova E, Zemankova P, Vocka M, et al.
Biomedicines
. 2020 Oct;
8(10).
PMID: 33050356
Cutaneous melanoma is the deadliest skin malignity with a rising prevalence worldwide. Patients carrying germline mutations in melanoma-susceptibility genes face an increased risk of melanoma and other cancers. To assess...
6.
Smetana Jr K, Lacina L, Kodet O
Cancers (Basel)
. 2020 Sep;
12(9).
PMID: 32899184
The incidence of cutaneous malignant melanoma (CMM) is significantly increasing worldwide.[...].
7.
Kodet O, Kucera J, Strnadova K, Dvorankova B, Stork J, Lacina L, et al.
Int J Oncol
. 2020 Jul;
57(3):619-630.
PMID: 32705148
The incidence of cutaneous malignant melanoma has been steadily increasing worldwide for several decades. This phenomenon seems to follow the trend observed in many types of malignancies caused by multiple...
8.
Strnadova K, Spanko M, Dvorankova B, Lacina L, Kodet O, Shbat A, et al.
Histochem Cell Biol
. 2020 Apr;
154(2):177-188.
PMID: 32232553
The globally increasing incidence of cancer, including melanoma, requires novel therapeutic strategies. Development of successful novel drugs is based on clear identification of the target mechanisms responsible for the disease...
9.
Ticha I, Hojny J, Michalkova R, Kodet O, Krkavcova E, Hajkova N, et al.
Sci Rep
. 2019 Nov;
9(1):17050.
PMID: 31745173
The most common histological subtypes of cutaneous melanoma include superficial spreading and nodular melanoma. However, the spectrum of somatic mutations developed in those lesions and all potential druggable targets have...
10.
Kucera J, Strnadova K, Dvorankova B, Lacina L, Krajsova I, Stork J, et al.
Oncol Rep
. 2019 Sep;
42(5):1793-1804.
PMID: 31545456
The steadily increasing incidence of malignant melanoma (MM) and its aggressive behaviour makes this tumour an attractive cancer research topic. The tumour microenvironment is being increasingly recognised as a key...